vs
Side-by-side financial comparison of SOLENO THERAPEUTICS INC (SLNO) and Voyager Technologies, Inc. (VOYG). Click either name above to swap in a different company.
SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $35.2M, roughly 1.9× Voyager Technologies, Inc.). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -130.4%, a 169.8% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $-66.8M).
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
SLNO vs VOYG — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $66.0M | $35.2M |
| Net Profit | $26.0M | $-45.9M |
| Gross Margin | 98.3% | -4.4% |
| Operating Margin | 33.5% | — |
| Net Margin | 39.4% | -130.4% |
| Revenue YoY | — | 2.1% |
| Net Profit YoY | 134.0% | -64.5% |
| EPS (diluted) | $0.47 | $-0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $35.2M | ||
| Q4 25 | — | $46.7M | ||
| Q3 25 | $66.0M | $39.6M | ||
| Q2 25 | $32.7M | $45.7M |
| Q1 26 | — | $-45.9M | ||
| Q4 25 | — | $-33.0M | ||
| Q3 25 | $26.0M | $-16.3M | ||
| Q2 25 | $-4.7M | $-31.4M |
| Q1 26 | — | -4.4% | ||
| Q4 25 | — | 21.4% | ||
| Q3 25 | 98.3% | 15.4% | ||
| Q2 25 | 97.9% | 18.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 33.5% | -60.7% | ||
| Q2 25 | -20.0% | -52.8% |
| Q1 26 | — | -130.4% | ||
| Q4 25 | — | -70.7% | ||
| Q3 25 | 39.4% | -41.1% | ||
| Q2 25 | -14.4% | -68.7% |
| Q1 26 | — | $-0.75 | ||
| Q4 25 | — | $-0.52 | ||
| Q3 25 | $0.47 | $-0.28 | ||
| Q2 25 | $-0.09 | $-1.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $498.9M | $429.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $494.8M | $404.5M |
| Total Assets | $599.9M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $429.4M | ||
| Q4 25 | — | $491.3M | ||
| Q3 25 | $498.9M | $413.3M | ||
| Q2 25 | $286.8M | $468.9M |
| Q1 26 | — | $404.5M | ||
| Q4 25 | — | — | ||
| Q3 25 | $494.8M | $590.9M | ||
| Q2 25 | $240.1M | $554.7M |
| Q1 26 | — | $1.0B | ||
| Q4 25 | — | — | ||
| Q3 25 | $599.9M | $727.8M | ||
| Q2 25 | $332.3M | $685.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.5M | $-39.7M |
| Free Cash FlowOCF − Capex | $43.5M | $-66.8M |
| FCF MarginFCF / Revenue | 65.8% | -189.5% |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-263.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-39.7M | ||
| Q4 25 | — | $-60.9M | ||
| Q3 25 | $43.5M | $-15.1M | ||
| Q2 25 | $-12.6M | $-30.9M |
| Q1 26 | — | $-66.8M | ||
| Q4 25 | — | $-54.5M | ||
| Q3 25 | $43.5M | $-53.8M | ||
| Q2 25 | $-12.6M | $-88.8M |
| Q1 26 | — | -189.5% | ||
| Q4 25 | — | -116.9% | ||
| Q3 25 | 65.8% | -135.8% | ||
| Q2 25 | -38.6% | -194.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | 97.8% | ||
| Q2 25 | 0.0% | 126.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.67× | — | ||
| Q2 25 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
